National Conference of the Italian Group for the Study of Neuromorphology
Vol. 70 No. s2 (2026): 36th National Conference of the Italian Group for the Study of...

OC18 | ENHANCED NEUROPROTECTION BY PRIMED ADIPOSE MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES IN AN IN VITRO MODEL OF ALS

D. Sganzerla, M. Caprioli, I. Scambi, A. D’Alberto, S. De Marchi, E. Pelullo, E. Turano, R. Mariotti | Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Italy

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 20 November 2026
0
Views
0
Downloads

Authors

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by the progressive loss of upper and lower motoneurons, leading to muscle weakness, paralysis, and ultimately respiratory failure. Despite intense research efforts, effective disease-modifying therapies remain unavailable. In recent years, extracellular vesicles derived from adipose mesenchymal stem cells (ASC-EVs) have attracted considerable attention as promising cell-free therapeutic agents owing to their neuroprotective, immunomodulatory, and anti-inflammatory properties. However, strategies aimed at further enhancing their therapeutic efficacy are still under investigation. In this study, we evaluated whether priming ASCs with pro-inflammatory stimuli could potentiate the neuroprotective activity of their released EVs in an in vitro model of ALS. The neuroprotective effects of ASC-EVs were assessed in NSC-34 motoneuron-like cells expressing human SOD1 (hSOD1) mutations associated with familial ALS (G93A, A4V, and G37R). Cell damage was induced through exposure to hydrogen peroxide (H2O2), resulting in approximately 50% cell death and providing a reproducible model of oxidative stress-related neurodegeneration. ASCs were preconditioned with either a cytokine cocktail or lipopolysaccharide (LPS), and EVs isolated from these cells were subsequently tested for their ability to promote motoneuron survival. Our findings revealed that EVs derived from primed ASCs exhibited markedly enhanced neuroprotective activity compared with EVs obtained from non-primed cells. Treatment with primed ASC-EVs significantly improved the viability of damaged SOD1-mutant motoneurons, suggesting that preconditioning enhances the biological properties of EV cargo and strengthens their capacity to counteract ALS-related pathogenic mechanisms. Overall, these results support the development of ASC-EV-based cell-free therapies for ALS and highlight cell priming as a promising strategy to maximize their therapeutic potential and translational value.

Downloads

Download data is not yet available.

Citations

How to Cite



1.
OC18 | ENHANCED NEUROPROTECTION BY PRIMED ADIPOSE MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES IN AN IN VITRO MODEL OF ALS: D. Sganzerla, M. Caprioli, I. Scambi, A. D’Alberto, S. De Marchi, E. Pelullo, E. Turano, R. Mariotti | Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Italy. Eur J Histochem [Internet]. 2026 Nov. 20 [cited 2026 Nov. 20];70(s2). Available from: https://www.ejh.it/ejh/article/view/4812